Plant Name: Clinacanthus nutans
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR5A; DRD1; HCAR2; HTR1A; HTR2B; HTR6; | |
| GAA; | |
| TDP1; CDA; HKDC1; HPGD; USP2; | |
| CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA6; | |
| MMP9; MMP1; MMP2; | |
| CREBBP; | |
| SLC28A1; SLC28A3; | |
| HTT; LMNA; F3; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | HKDC1 | Putative hexokinase HKDC1 | Q2TB90 | CHEMBL1741200 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.853E-11 | 2.138E-07 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, CDA, CREBBP, MMP1, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 6.975E-10 | 1.266E-06 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 6.975E-10 | 1.266E-06 | HTR1A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 3.321E-09 | 4.520E-06 | HTR1A, HTR2B, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 2.375E-08 | 2.722E-05 | HTR1A, HTR5A, HTR7 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.184E-07 | 1.121E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.816E-25 | 8.310E-21 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.293E-06 | 1.005E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.377E-06 | 2.372E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.935E-06 | 5.450E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.012E-05 | 5.450E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.012E-05 | 5.450E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.012E-05 | 5.450E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.012E-05 | 5.450E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.026E-05 | 5.450E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.022E-05 | 9.570E-03 | CYP1A2, CYP3A4 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 2.101E-05 | 9.735E-03 | HTR1A, HTR2B, HTR7 |
| BP | GO:0009987; cellular process | GO:0007187; G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 2.147E-05 | 9.738E-03 | DRD1, HTR1A, HTR5A, HTR6, HTR7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.043E-19 | 3.313E-15 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.320E-18 | 4.529E-14 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.741E-24 | 1.463E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.577E-08 | 1.922E-06 | HTR6; HTR7; CYP2D6; HTR1A; HTR2B; HTR5A |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 9.185E-06 | 2.572E-04 | HTR6; HTR7; HTR1A; HTR2B; DRD1; HTR5A |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.679E-05 | 3.527E-04 | HTR6; HTR7; HTR2B; DRD1; HTR5A |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.721E-05 | 4.571E-04 | HCAR2; CREBBP; HTR6; HTR1A; DRD1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.447E-05 | 7.626E-04 | MMP1; MMP2; MMP9 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.586E-04 | 3.103E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.055E-04 | 3.208E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.454E-03 | 3.272E-02 | CREBBP; MMP1; MMP2; MMP9 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 4.564E-03 | 3.158E-02 | GAA; HKDC1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.240E-03 | 1.115E-02 | CYP1A2; CYP3A4 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.102E-03 | 2.369E-02 | CDA; CYP3A4 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.328E-03 | 1.115E-02 | GAA; HKDC1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.888E-03 | 3.158E-02 | CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.102E-03 | 3.417E-02 | CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.241E-03 | 3.802E-02 | CA2; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.094E-02 | 4.596E-02 | HTR2B; DRD1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.558E-03 | 4.226E-02 | CYP1A2; CYP3A4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.969E-03 | 4.185E-02 | CYP1A2 |
| hsa00524 | Butirosin and neomycin biosynthesis_Homo sapiens_hsa00524 | 8.969E-03 | 4.185E-02 | HKDC1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1 |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; HTR1A; HTR1A; HTR6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MMP9; MMP2; CDA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; HTR1A |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; F3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6 |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B |
| NA: NA | Social phobia | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; HTR6 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2B; HTR1A |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HCAR2; HTR1A; HTR1A |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| NA: NA | Episode | NA | HTR1A |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; MAPT; HTR1A; HTR6 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2B; HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; HTR1A; HTR1A; HTR6; HTR6; HTR6 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HCAR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; HCAR2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MMP9; MMP2 |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| NA: NA | Anxiety disorders | NA | HTR1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; HTR1A |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| NA: NA | Cervical dystonia | NA | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; HTR1A; HTR6; HTR6 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP |
| I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP |